PT  - JOURNAL ARTICLE
AU  - Ma, Kevin C.
AU  - Hale, Jaime E.
AU  - Grad, Yonatan H.
AU  - Alter, Galit
AU  - Luzuriaga, Katherine
AU  - Eaton, Roger B.
AU  - Fischinger, Stephanie
AU  - Kaur, Devinder
AU  - Brody, Robin
AU  - Siddiqui, Sameed M.
AU  - Leach, Dylan
AU  - Brown, Catherine M.
AU  - Klevens, R. Monina
AU  - Madoff, Lawrence
AU  - Comeau, Anne Marie
TI  - Trends in SARS-CoV-2 seroprevalence in Massachusetts estimated from newborn screening specimens
AID  - 10.1101/2021.10.29.21265678
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.29.21265678
4099  - http://medrxiv.org/content/early/2021/10/30/2021.10.29.21265678.short
4100  - http://medrxiv.org/content/early/2021/10/30/2021.10.29.21265678.full
AB  - Background Estimating the cumulative incidence of SARS-CoV-2 is essential for setting public health policies. We leveraged de-identified Massachusetts newborn screening specimens to generate an accessible, retrospective source of maternal antibodies for estimating statewide SARS-CoV-2 seroprevalence in a non-test-seeking population.Methods We analyzed 72,117 newborn dried blood spots collected from November 2019 through December 2020, representing 337 towns and cities across Massachusetts. Seroprevalence was estimated for the general Massachusetts population after correcting for imperfect test specificity and nonrepresentative sampling using Bayesian multilevel regression and poststratification.Results Statewide seroprevalence was estimated to be 0.03% (90% credible interval (CI) [0.00, 0.11]) in November 2019 and rose to 1.47% (90% CI [1.00, 2.13]) by May 2020, following sustained SARS-CoV-2 transmission in the spring. Seroprevalence plateaued from May onwards, reaching 2.15% (90% CI [1.56, 2.98]) in December 2020. Seroprevalence varied substantially by community and was particularly associated with community percent non-Hispanic Black (β = 0.024, 90% CI [0.004, 0.044]); i.e., a 10% increase in community percent non-Hispanic Black was associated with a 27% higher odds of seropositivity. Seroprevalence estimates had good concordance with reported case counts and wastewater surveillance for most of 2020, prior to the resurgence of transmission in winter.Conclusions Cumulative incidence of SARS-CoV-2 protective antibody in Massachusetts was low as of December 2020, indicating that a substantial fraction of the population was still susceptible. Maternal seroprevalence data from newborn screening can inform longitudinal trends and identify cities and towns at highest risk, particularly in settings where widespread diagnostic testing is unavailable.Summary The measurement of maternal antibodies in dried blood spots collected for newborn screening offers a statewide source of SARS-CoV-2 seroprevalence data independent of case testing limitations. We analyzed 72,117 Massachusetts spots collected November 2019 – December 2020 and estimated longitudinal trends.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Science Foundation GRFP (DGE1745303 to K.C.M.); the Morris-Singer Foundation to Y.H.G.; the U.S. Food and Drug Administration (HHSF223201810172C to S.M.S.); the UMass Center for Clinical and Translational Science (NIH UL1TR001453 to K.L.); and the Centers for Disease Control and Prevention (contract 200-2016-91779). The findings, conclusions, and views expressed in this presentation are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of the Massachusetts Department of Public Health and the UMass Chan Medical School approved waivers of consent for the de-identified public health surveillance.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese data contain personal identifying health information and are not available for public use or dissemination. Code used for model fitting is available at the following URL: https://github.com/gradlab/covid19-newborn-seroprevalence